Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01763606 · ClinicalTrials.gov registry record · NA
Enoxaparin Versus Aspirin in Patients With Cancer and Stroke
A NA study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT01763606: Completed NA study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01763606 is a NA study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01763606, a NA study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
Patients with cancer who develop stroke are at high risk for future strokes or other clotting events. These patients are routinely treated with medicines that thin their blood, including enoxaparin or aspirin. However, it is unclear which medicine is best and whether these medicines can be adequately studied in a clinical trial. The purpose of this Phase I/II study is to determine if a clinical trial of different blood thinners in patients with cancer and stroke is possible. In addition, the study aims to compare the effects, good and/or bad, of enoxaparin with those of aspirin on patients with cancer and recent stroke.
Interventions
- DRUG Aspirin
- DRUG Enoxaparin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2012-12-18 |
| Est. Completion | 2019-04-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01763606
The ClinicalTrials.gov registry entry for NCT01763606 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aspirin is the first listed.
NCT01763606 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01763606 about?
NCT01763606 is a clinical study titled "Enoxaparin Versus Aspirin in Patients With Cancer and Stroke". Patients with cancer who develop stroke are at high risk for future strokes or other clotting events. These patients are routinely treated with medicines that thin their blood, including enoxaparin or aspirin. However, it is unclear which medicine is best and whether these medicines can be adequatel...
What is the current status of trial NCT01763606?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2012-12-18. Estimated completion is 2019-04-03.
What interventions are being tested in trial NCT01763606?
The interventions under investigation include: Aspirin (DRUG), Enoxaparin (DRUG).
Who is sponsoring clinical trial NCT01763606?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.